Vendor review
Hebei Rimao Technology reviews
Hebei Rimao Technology reviews from 64 independent lab tests (Retatrutide, Tirzepatide and BPC-157): grade A, purity and fill accuracy. Is Hebei Rimao Technology legit? See what its vials showed.
Grade A64 independent lab tests0 peptides listedShips from China
Hebei Rimao Technology's website could not be reached at the last check. Links to the shop are disabled.
What the lab tests show
64 tests on record, newest first. Scores are purity divided by ten.
| Date | Product | Purity | Quantity | Identity | Certificate |
|---|---|---|---|---|---|
| Jun 26, 2026 | Tirzepatide | 99.8 % | 45.3 mg of 40 mg (13 %) | Pass | View |
| Jun 26, 2026 | Retatrutide | 30 mg | View | ||
| Jun 26, 2026 | Tirzepatide | 40 mg | View | ||
| Jun 26, 2026 | Retatrutide | 99.8 % | 35.7 mg of 30 mg (19 %) | Pass | View |
| May 9, 2026 | Retatrutide | 99.9 % | 19.3 mg of 20 mg (-3 %) | Pass | View |
| May 8, 2026 | Retatrutide | 99.9 % | 19.8 mg of 20 mg (-1 %) | Pass | View |
| May 6, 2026 | Tesamorelin | 99.9 % | 7.41 mg of 10 mg (-26 %) | Pass | View |
| May 6, 2026 | TB-500 | 99.3 % | 10.2 mg of 10 mg (2 %) | Pass | View |
| May 5, 2026 | CJC-1295 | 5 mg | Fail | View | |
| Apr 23, 2026 | GHK-Cu | 99.9 % | 65.1 mg of 100 mg (-35 %) | Pass | View |
| Apr 23, 2026 | Tirzepatide | 30 mg | Fail | View | |
| Apr 23, 2026 | CJC-1295 | 2 mg | Fail | View | |
| Mar 4, 2026 | BPC-157 | 98.72 % | 10.9 mg of 10 mg (9 %) | Pass | View |
| Mar 1, 2026 | Retatrutide | 99.7 % | 19.2 mg of 20 mg (-4 %) | Pass | View |
| Mar 1, 2026 | Retatrutide | 99.7 % | 20.3 mg of 20 mg (2 %) | Pass | View |
| Mar 1, 2026 | Retatrutide | 99.6 % | 20.3 mg of 20 mg (2 %) | Pass | View |
| Mar 1, 2026 | Retatrutide | 99.7 % | 19 mg of 20 mg (-5 %) | Pass | View |
| Mar 1, 2026 | Cagrilintide | 99.4 % | 10.1 mg of 10 mg (1 %) | Pass | View |
| Feb 26, 2026 | Tirzepatide | 92.26 % | 11 mg of 10 mg (10 %) | Pass | View |
| Feb 26, 2026 | GHK-Cu | 99.72 % | 48.6 mg of 50 mg (-3 %) | Pass | View |
| Feb 26, 2026 | Tesamorelin | 98.32 % | 5.13 mg of 5 mg (3 %) | Pass | View |
| Feb 25, 2026 | Tirzepatide | 99.9 % | 11.2 mg of 30 mg (-63 %) | Pass | View |
| Feb 22, 2026 | Retatrutide | 99.84 % | 22.1 mg of 20 mg (11 %) | Pass | View |
| Feb 20, 2026 | BPC-157 | 99.7 % | 14.6 mg of 10 mg (46 %) | Pass | View |
| Feb 20, 2026 | Tirzepatide | 99.86 % | 35 mg of 30 mg (17 %) | Pass | View |
| Feb 20, 2026 | TB-500 | 99.7 % | 16.6 mg of 10 mg (66 %) | Pass | View |
| Feb 20, 2026 | CJC-1295 | 98.24 % | 10.3 mg of 10 mg (3 %) | Pass | View |
| Feb 18, 2026 | Tirzepatide | 98.66 % | 30.5 mg of 30 mg (2 %) | Pass | View |
| Feb 18, 2026 | Tirzepatide | 99.9 % | 10.2 mg of 10 mg (2 %) | Pass | View |
| Feb 18, 2026 | Tirzepatide | 99.72 % | 22.9 mg of 20 mg (15 %) | Pass | View |
| Feb 18, 2026 | Cagrilintide | 99.9 % | 4.64 mg of 5 mg (-7 %) | Pass | View |
| Feb 11, 2026 | Retatrutide | 99.9 % | 21.1 mg of 20 mg (6 %) | Pass | View |
| Feb 11, 2026 | BPC-157 | 99.9 % | 8.53 mg of 10 mg (-15 %) | Pass | View |
| Feb 11, 2026 | Tirzepatide | 99.9 % | 29.9 mg of 30 mg (0 %) | Pass | View |
| Feb 11, 2026 | Retatrutide | 99.9 % | 32.4 mg of 30 mg (8 %) | Pass | View |
| Feb 11, 2026 | Tesamorelin | 99.9 % | 10.8 mg of 10 mg (8 %) | Pass | View |
| Feb 9, 2026 | GHK-Cu | 99.9 % | 50 mg of 50 mg (0 %) | Pass | View |
| Feb 9, 2026 | Retatrutide | 98.79 % | 1.77 mg of 5 mg (-65 %) | Pass | View |
| Feb 9, 2026 | BPC-157 | 99.9 % | 6.73 mg of 10 mg (-33 %) | Pass | View |
| Feb 6, 2026 | TB-500 | 99.9 % | 11 mg of 10 mg (10 %) | Pass | View |
| Feb 2, 2026 | Tirzepatide | 99.03 % | 11 mg of 10 mg (10 %) | Pass | View |
| Jan 19, 2026 | Tesamorelin | 99.95 % | 11 mg of 10 mg (10 %) | Pass | View |
| Jan 7, 2026 | Tirzepatide | 99.9 % | 44.1 mg of 40 mg (10 %) | Pass | View |
| Jan 6, 2026 | GHK-Cu | 99.8 % | 46.2 mg of 50 mg (-8 %) | Pass | View |
| Dec 29, 2025 | Tirzepatide | 99.6 % | 9.9 mg of 10 mg (-1 %) | Pass | View |
| Dec 18, 2025 | Tirzepatide | 99.8 % | 34.5 mg of 30 mg (15 %) | Pass | View |
| Dec 17, 2025 | Tirzepatide | 99.73 % | 18 mg of 20 mg (-10 %) | Pass | View |
| Dec 17, 2025 | Retatrutide | 99.95 % | 18.9 mg of 20 mg (-6 %) | Pass | View |
| Dec 11, 2025 | GHK-Cu | 99.79 % | 49.9 mg of 50 mg (0 %) | Pass | View |
| Dec 11, 2025 | BPC-157 | 99.01 % | 5.16 mg of 5 mg (3 %) | Pass | View |
| Oct 24, 2025 | Retatrutide | 99.427 % | 11.34 mg of 10 mg (13 %) | Pass | View |
| Oct 24, 2025 | Tirzepatide | 99.9 % | 62.31 mg of 60 mg (4 %) | Pass | View |
| Oct 17, 2025 | Retatrutide | 99.95 % | 19.3 mg of 20 mg (-3 %) | Pass | View |
| Oct 6, 2025 | Retatrutide | 99.7 % | 22.7 mg of 20 mg (14 %) | Pass | View |
| Oct 3, 2025 | Retatrutide | 99.79 % | 9.24 mg of 10 mg (-8 %) | Pass | View |
| Sep 30, 2025 | Tirzepatide | 99.74 % | 9.67 mg of 20 mg (-52 %) | Pass | View |
| Sep 30, 2025 | Tirzepatide | 99.95 % | 58.1 mg of 60 mg (-3 %) | Pass | View |
| Sep 30, 2025 | Retatrutide | 99.77 % | 4.72 mg of 5 mg (-6 %) | Pass | View |
| Sep 19, 2025 | Retatrutide | 99.95 % | 16.2 mg of 15 mg (8 %) | Pass | View |
| Sep 9, 2025 | Tesamorelin | 96.985 % | 4.99 mg of 5 mg (0 %) | Pass | View |
What Hebei Rimao Technology sells
No current listings on record.
About Hebei Rimao Technology
Finnrick has tested 64 samples from Hebei Rimao Technology across 8 products.